# David S P Tan

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 72 papers | 4,160 citations | 30 h-index | 64 g-index |
| 89 ext. papers | 5,055 ext. citations | 7.3 avg, IF | 5.41 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 72 | "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *Journal of Clinical Oncology*, **2008**, 26, 5530-6 | 2.2 | 367 |
| 71 | Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. *Nature Reviews Cancer*, **2013**, 13, 273-82 | 31.3 | 331 |
| 70 | Mechanisms of transcoelomic metastasis in ovarian cancer. *Lancet Oncology, The*, **2006**, 7, 925-34 | 21.7 | 320 |
| 69 | ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease *Annals of Oncology*, **2019**, 30, 672-705 | 10.3 | 298 |
| 68 | Breast cancer molecular profiling with single sample predictors: a retrospective analysis. *Lancet Oncology, The*, **2010**, 11, 339-49 | 21.7 | 274 |
| 67 | Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. *Breast Cancer Research and Treatment*, **2008**, 111, 27-44 | 4.4 | 257 |
| 66 | Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. *Journal of Pathology*, **2009**, 219, 16-24 | 9.4 | 164 |
| 65 | Tiling path genomic profiling of grade 3 invasive ductal breast cancers. *Clinical Cancer Research*, **2009**, 15, 2711-22 | 12.9 | 138 |
| 64 | An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. *Breast Cancer Research and Treatment*, **2010**, 121, 575-89 | 4.4 | 132 |
| 63 | PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. *Clinical Cancer Research*, **2009**, 15, 2269-80 | 12.9 | 128 |
| 62 | Biomarkers for Homologous Recombination Deficiency in Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 704-713 | 9.7 | 122 |
| 61 | Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. *Laboratory Investigation*, **2008**, 88, 491-503 | 5.9 | 116 |
| 60 | Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. *Journal of the National Cancer Institute*, **2011**, 103, 662-73 | 9.7 | 105 |
| 59 | Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. *Clinical Cancer Research*, **2011**, 17, 1521-34 | 12.9 | 100 |
| 58 | Ovarian clear cell adenocarcinoma: a continuing enigma. *Journal of Clinical Pathology*, **2007**, 60, 355-60 | 3.9 | 89 |
| 57 | Are triple-negative tumours and basal-like breast cancer synonymous?. *Breast Cancer Research*, **2007**, 9, 404; author reply 405 | 8.3 | 83 |
| 56 | Weekly paclitaxel in the treatment of recurrent ovarian cancer. *Nature Reviews Clinical Oncology*, **2010**, 7, 575-82 | 19.4 | 74 |

| | | | |
|---|---|---|---|
| 55 | Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. *Genes Chromosomes and Cancer*, **2009**, 48, 351-65 | 5 | 74 |
| 54 | New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. *British Journal of Cancer*, **2013**, 108, 1553-9 | 8.7 | 71 |
| 53 | The genomic profile of HER2-amplified breast cancers: the influence of ER status. *Journal of Pathology*, **2008**, 216, 399-407 | 9.4 | 69 |
| 52 | Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. *Cancer Discovery*, **2014**, 4, 527-37 | 24.4 | 67 |
| 51 | Appraising iniparib, the PARP inhibitor that never was--what must we learn?. *Nature Reviews Clinical Oncology*, **2013**, 10, 688-96 | 19.4 | 66 |
| 50 | Getting it right: designing microarray (and not Qnicroawry Qcomparative genomic hybridization studies for cancer research. *Laboratory Investigation*, **2007**, 87, 737-54 | 5.9 | 62 |
| 49 | Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. *Laboratory Investigation*, **2007**, 87, 75-83 | 5.9 | 52 |
| 48 | CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. *Oncotarget*, **2015**, 6, 43843-52 | 3.3 | 46 |
| 47 | Update on immune checkpoint inhibitors in gynecological cancers. *Journal of Gynecologic Oncology*, **2017**, 28, e20 | 4 | 45 |
| 46 | First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. *Cancer Discovery*, **2021**, 11, 80-91 | 24.4 | 45 |
| 45 | Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. *Journal of Translational Medicine*, **2015**, 13, 57 | 8.5 | 42 |
| 44 | Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. *Scientific Reports*, **2018**, 8, 12248 | 4.9 | 35 |
| 43 | Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, 114-21 | 7.1 | 34 |
| 42 | A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. *Clinical Cancer Research*, **2018**, 24, 6168-6174 | 12.9 | 30 |
| 41 | Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. *EBioMedicine*, **2019**, 50, 203-210 | 8.8 | 25 |
| 40 | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. *Cancers*, **2017**, 9, | 6.6 | 22 |
| 39 | Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. *European Journal of Cancer*, **2013**, 49, 1246-53 | 7.5 | 20 |
| 38 | The importance of gene-centring microarray data AuthorsQreply. *Lancet Oncology, The*, **2010**, 11, 720-721 | 11.7 | 18 |

| | | | |
|---|---|---|---|
| 37 | ESR1 amplification in endometrial carcinomas: hope or hyperbole?. *Journal of Pathology*, **2008**, 216, 271-4 | 5.4 | 17 |
| 36 | Development of therapeutic approaches to triple negative phenotype breast cancer. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 1123-37 | 6.4 | 16 |
| 35 | Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer. *Pathobiology*, **2008**, 75, 63-74 | 3.6 | 15 |
| 34 | A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI?9041). *Investigational New Drugs*, **2016**, 34, 104-11 | 4.3 | 13 |
| 33 | The systemic treatment of recurrent ovarian cancer revisited. *Annals of Oncology*, **2021**, 32, 710-725 | 10.3 | 13 |
| 32 | Development of PARP inhibitors in gynecological malignancies. *Current Problems in Cancer*, **2017**, 41, 273-286 | 2.3 | 12 |
| 31 | The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. *ESMO Open*, **2021**, 6, 100144 | 6 | 12 |
| 30 | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?. *Journal of Gynecologic Oncology*, **2018**, 29, e96 | 4 | 12 |
| 29 | Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?. *BMC Cancer*, **2019**, 19, 385 | 4.8 | 11 |
| 28 | Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers. *Oncotarget*, **2018**, 9, 30649-30660 | 3.3 | 11 |
| 27 | Targeting the replication stress response through synthetic lethal strategies in cancer medicine. *Trends in Cancer*, **2021**, 7, 930-957 | 12.5 | 11 |
| 26 | Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. *International Journal of Cancer*, **2018**, 142, 1890-1900 | 7.5 | 10 |
| 25 | Targeting the AXL signaling pathway in ovarian cancer. *Molecular and Cellular Oncology*, **2017**, 4, e1263716 | 1.2 | 8 |
| 24 | Ovarian cancer: can we reverse drug resistance?. *Advances in Experimental Medicine and Biology*, **2008**, 622, 153-67 | 3.6 | 8 |
| 23 | Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. *Gynecologic Oncology Reports*, **2018**, 24, 1-5 | 1.3 | 7 |
| 22 | Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. *EMBO Molecular Medicine*, **2021**, 13, e13366 | 12 | 7 |
| 21 | Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. *PLoS ONE*, **2016**, 11, e0164319 | 3.7 | 6 |
| 20 | A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). *International Journal of Gynecological Cancer*, **2020**, 30, 1239-1242 | 3.5 | 5 |

| | | | |
|---|---|---|---|
| 19 | Exploiting replicative stress in gynecological cancers as a therapeutic strategy. *International Journal of Gynecological Cancer*, **2020**, 30, 1224-1238 | 3.5 | 5 |
| 18 | The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 4 |
| 17 | A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). *Journal of Gynecologic Oncology*, **2021**, 32, e31 | 4 | 4 |
| 16 | Immune checkpoint inhibitors in ovarian cancer: where do we stand?. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211039899 | 5.4 | 4 |
| 15 | Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.. *Cancer Treatment Reviews*, **2022**, 106, 102385 | 14.4 | 4 |
| 14 | Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01). *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 701-711 | 4 | 2 |
| 13 | Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutation-Associated Ovarian Cancer.. *JCO Precision Oncology*, **2018**, 2, 1-8 | 3.6 | 2 |
| 12 | Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.. *The Cochrane Library*, **2022**, 2, CD012007 | 5.2 | 2 |
| 11 | Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with ovarian cancer. *The Cochrane Library*, **2015**, | 5.2 | 1 |
| 10 | Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with -mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. *Journal of Gynecologic Oncology*, **2021**, 32, e27 | 4 | 1 |
| 9 | Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma. *Metabolites*, **2021**, 11, | 5.6 | 1 |
| 8 | A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359221087555 | 5.4 | 1 |
| 7 | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report. *OncoTargets and Therapy*, **2021**, 14, 3921-3928 | 4.4 | 0 |
| 6 | A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma. *Journal of Pathology*, **2021**, 255, 285-295 | 9.4 | 0 |
| 5 | Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives. *Frontiers in Oncology*, **2021**, 11, 736265 | 5.3 | 0 |
| 4 | Microarray-Based Comparative Genomic Hybridization135-161 | | |
| 3 | Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. *Current Cancer Therapy Reviews*, **2016**, 12, 23-36 | 0.4 | |
| 2 | The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2021**, 78, 14-14 | 4.6 | |

1 Combined modality management of advanced cervical cancer including novel sensitizers.. *International Journal of Gynecological Cancer*, **2022**, 32, 246-259 3.5